Clinical trial NCT02398448: IVIVR Assessing PK Parameters Used to Establish Bioequivalence
Official title: In Vitro-In Vivo Relationship Study to Assess the Impact of the In Vitro Dissolution Profile on the Pharmacokinetic Parameters Used to Establish Bioequivalence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Ardea Biosciences, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Quotient Clinical
First posted: 2015-03-25
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether defined and limited changes in in vitro dissolution impact the in vivo pharmacokinetics (PK) and relative bioavailability of allopurinol and the active metabolite oxypurinol.

Detailed description: In this study, a single oral dose of Zyloprim® (300 mg tablet) and 3 separate single oral doses of 300 mg allopurinol test formulations (Regimens B, C and D) will be administered sequentially to each subject on separate occasions. Following the administration of Regimens B and C, there will be a period of interim analysis during which the PK data will be reviewed to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period.

Eligibility criteria: Inclusion Criteria:

* Body mass index of 18.0 to 35.0 kg/m2 inclusive, or if outside the range, considered not clinically significant by the Investigator. Must not exceed 40.0 kg/m2.
* Must agree to use an adequate method of contraception

Exclusion Criteria:

* Subjects who test positive for the HLA-B\*5801 allele.
* Subjects who have received the last dose of an IMP (or treatment with a medical device) within the previous 3 months prior to Day 1 or is currently participating in another study of an IMP (or medical device).
* History of any drug or alcohol abuse in the past 2 years.
* Regular alcohol consumption in males \>21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).
* Current smokers and those who have smoked within the last 12 months prior to Screening. A breath carbon monoxide reading of greater than 10 ppm at Screening.
* Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator at Screening.
* Clinically significant screening laboratory parameters (biochemistry \[AST or ALT \> 1.5 × ULN\], hematology or urinalysis) as judged by the Investigator (laboratory parameters are listed in Appendix 1).
* Positive drugs of abuse test result during Screening or at Admission (drugs of abuse tests are listed in Appendix 1).
* Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results.
* Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
* History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the Investigator.
* Evidence of renal impairment at Screening, as indicated by an estimated creatinine clearance of \<90 mL/min using the Cockcroft-Gault equation.
* Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients.
* Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hayfever is allowed unless it is active.
* Donation or loss of greater than 400 mL of blood within the previous 3 months prior to Screening.
* Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than up to 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration (See Section 11.4).

Primary outcomes:
measure: PK profile of Zyloprim® and three dissolution test formulations of allopurinol from plasma
timeFrame: Predose (within 30 minutes before dosing), 15, 30, and 45 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours postdose.
Secondary outcomes:
measure: Incidence of Adverse Events
timeFrame: 11 weeks
Other outcomes:
Locations:
city: Ruddington
country: United Kingdom
Study officials:
affiliation: Ardea Biosciences, Inc.
name: Chris Storgard
role: STUDY_DIRECTOR
References: